Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers

Phase 1 Completed 40 enrolled Boehringer Ingelheim

RandomizedCrossoverOpen-labelTreatment

Summary

Study to determine the single dose, relative BA of new SDS-containing formulations of BILR 355 (150 mg and 200 mg capsules and 150 mg tablet), compared to the current SDS tablet formulation (50 mg tablet)

Timeline

Start: 2006-10
Primary completion: 2006-12
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BILR 355	Small molecule	50 mg	Oral
Subject	BILR 355	Small molecule	150 mg	Oral
Subject	BILR 355	Small molecule	200 mg	Oral
Background	Ritonavir	Other / unclassified	—	Oral

Indications

No indication recorded.